Loading...
Although standard influenza vaccination is moderately helpful in protecting elders from seasonal influenza, the ongoing burden of disease in this age group mandates something better. In 2009, a high-dose inactivated vaccine preparation that contained four times the standard amount of antigen (NEJM JW Gen Med Aug 11 2009) was licensed for use in adults 65 and older on the basis of its safety and promising immunogenicity, with the caveat that clinical benefits had yet to be demonstrated. Now, researchers have provided those data in a manufacturer-supported trial conducted during the 2011–2012 and 2012–2013 flu seasons in 32,000 older adults (mean age, 73; most with ≥1 chronic medical conditions; none seriously ill) at 126 centers in the U.S. …